RB-0003

N/A

Report date: 2026/05/12 09:09:06

Base Information

Drug NameRB-0003

Drug Alias NameLipo-MERITRNA-LPXTetravalent RNA-lipoplex Cancer VaccineRB 0003RBL001.1/RBL002.2 /RBL003.1/RBL004.1 +[8]

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionCluster of differentiation 8 stimulantsT-cell surface antigen CD4 agonists

TargetsT-cell surface antigen CD4Cluster of differentiation 8

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPolandItaly +[7]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesBiontech Se Tron

China Registration ClassN/A

Develop Information

Active CompaniesBiontech Se

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A